The Human Element in Drug Development
At AVIGI Therapeutics, we hold a fundamental belief: while molecules form the basis of medicines, it's the ingenuity of people that drives breakthroughs. In today's advanced landscape of drug development, AI analyses data and robots labs conduct experiments. But we've acknowledged and hold deeply that our greatest strength lies not just in our tools, but in the collaborative efforts and innovative minds that propel our programs forward.
The Development Team
Vincent Lit, PhD: Founder & CEO
Vincent has obtained his PhD from Leiden University and decided to translate his academic discoveries into a company that can make an impact in medicine development. LinkedIn
Dilara Masri, MSc: Science & Business Associate
Dilara is a pharmacist by training and clinical epidemiologist, bringing a holistic approach to drug development and real-world medicine use. LinkedIn
Arian Khoshchin, MSc: Founder & CBO
Arian is a start-up operator, trained in Biopharmaceutical Sciences and Industrial Pharmacy with a decade of biopharma development experience. LinkedIn
Advisors
Prof. Herman Overkleeft
Scientific Advisor
Herman is an expert in glycosidase chemical biology. His research led to the creation of Azafaros, a biotech company that successfully advanced glycoprocessing enzyme inhibitors to clinical trials.
Dr. Alessandro Noseda
Medical Advisor
Alessandro is a medical doctor and global drug development leader with over 30 years of experience in the pharma and biotech sector. He headed development of previous class of heparanase inhibitors to phase 2 trials.
Prof. Gideon Davies
Scientific Advisor
Gideon is a renowned scientist and academic. He is best known for his work on carbohydrate-active enzymes, notably analyzing the conformational and mechanistic basis for catalysis and applying this for societal benefit.
Dr. Liang Wu
Scientific Advisor
Liang studied Medicinal Chemistry at UCL, followed by a PhD at Cambridge studying the interactions between proteins and noncoding RNAs. He then moved to York for a postdoc, investigating the structures of sugar processing enzymes and their roles in biology, which is where his interest remains today.
Prof. Dr. Adam Cohen
Clinical Advisor
Adam is a world class clinical pharmacologist and physician. He has been involved in early drug development, including the initial human trials of lamotrigine, a key treatment for epilepsy and bipolar disorder. He founded CHDR in Leiden, a leading early-phase CRO, and has held roles such as chairman of the Netherlands Competent Authority for Clinical Trials and Editor in Chief of the British Journal of Clinical Pharmacology.